Sugi Predict

Sugi Predict / Compounds / SCHEMBL2087785

SCHEMBL2087785

SCHEMBL2087785

CCn1c(C)c(C(=O)/C=C/N(C)C)sc1=O

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.44
▸ MAPT P10636 8/20 0.40
▸ ALDH1A1 P00352 8/20 0.39
▸ RAB9A P51151 7/20 0.39
▸ KMT2A Q03164 4/20 0.39
▸ NPC1 O15118 4/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ TDP1 Q9NUW8 2/20 0.36
▸ LMNA P02545 3/20 0.35
▸ RECQL P46063 2/20 0.35
▸ HPGD P15428 2/20 0.35
▸ CYP1A2 P05177 2/20 0.33
▸ CYP2C19 P33261 2/20 0.33
▸ HTT P42858 1/20 0.33
▸ ALOX12 P18054 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2087788 1.00 POLB (0.44) POLBMAPTALDH1A1RAB9AKMT2A
SCHEMBL2075578 0.80 POLB (0.47) POLBMAPTALDH1A1RAB9AKMT2A
SCHEMBL2075580 0.80 POLB (0.47) POLBMAPTALDH1A1RAB9AKMT2A
SCHEMBL11400671 0.74 LMNA (0.39) POLBMAPTALDH1A1RAB9AKDM4E
SCHEMBL2084813 0.66 POLB (0.49) POLBMAPTALDH1A1RAB9AKMT2A
SCHEMBL2084815 0.66 POLB (0.49) POLBMAPTALDH1A1RAB9AKMT2A
SCHEMBL4826666 0.66 RAB9A (0.37) POLBMAPTALDH1A1RAB9AKMT2A
SCHEMBL18453167 0.66 ALDH1A1 (0.56) POLBMAPTALDH1A1RAB9AKMT2A
SCHEMBL18453943 0.66 ALDH1A1 (0.56) POLBMAPTALDH1A1RAB9AKMT2A
SCHEMBL4826664 0.66 RAB9A (0.37) POLBMAPTALDH1A1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11970491-B2 N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds AUCENTRA THERAPEUTICS PTY LTD (AU) 2024-04-30 — — US disclosed
US-RE49850-E1 N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds AUCENTRA THERAPEUTICS PTY LTD (AU) 2024-02-27 — — US disclosed
EP-3957637-B1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS AUCENTRA THERAPEUTICS PTY LTD (AU) 2023-06-28 — — EP disclosed
EP-3331880-B3 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS AUCENTRA THERAPEUTICS PTY LTD (AU) 2023-01-11 — — EP disclosed
US-20220267315-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS AUCENTRA THERAPEUTICS PTY LTD (AU) 2022-08-25 — — US disclosed
EP-3957637-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS Aucentra Therapeutics Pty Ltd (AU) 2022-02-23 — — EP disclosed
EP-3331880-B1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS AUCENTRA THERAPEUTICS PTY LTD (AU) 2021-12-01 — — EP disclosed
CN-113336746-A N- (pyridin-2-yl) -4- (thiazol-5-yl) pyrimidin-2-amines as therapeutic compounds 常州千红生化制药股份有限公司 2021-09-03 — — CN disclosed
CN-108349964-B N- (pyridin-2-yl) -4- (thiazol-5-yl) pyrimidin-2-amines as therapeutic compounds 常州千红生化制药股份有限公司 2021-06-01 — — CN disclosed
US-20200283431-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS AUCENTRA THERAPEUTICS PTY LTD (AU) 2020-09-10 — — US disclosed
US-10479785-B2 N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds AUCENTRA THERAPEUTICS PTY LTD (AU) 2019-11-19 — — US disclosed
US-20180222900-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS AUCENTRA THERAPEUTICS PTY LTD (AU) 2018-08-09 — — US disclosed
EP-1678171-B1 2-AMINO-4-THIAZOLONE-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS CYCLACEL LTD (GB) 2016-09-14 — — EP disclosed
US-7902361-B2 Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy CYCLACEL LIMITED (GB) 2011-03-08 — — US disclosed
US-20070021452-A1 Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy CYCLACEL LIMITED (GB) 2007-01-25 — — US disclosed
EP-1678171-A1 PYRIMIDIN-4-YL-3,4-THIONE COMPOUNDS AND THEIR USE IN THERAPY Cyclacel Limited (GB) 2006-07-12 — — EP disclosed
WO-2005042525-A1 PYRIMIDIN-4-YL-3, 4-THIONE COMPOUNDS AND THEIR USE IN THERAPY CYCLACEL LIMITED (GB) 2005-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180222900-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS CDK4, CDK6, CDK2 POLB 1213/4885MAPT 1190/4885ALDH1A1 3569/4885
US-20070021452-A1 Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy MSRB3, DHFR, CBR3 POLB 759/4885MAPT 2989/4885ALDH1A1 2669/4885
US-10479785-B2 N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds CDK4, CDK6, CDK2 POLB 1213/4885MAPT 1190/4885ALDH1A1 3569/4885
US-20200283431-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS CDK4, CDK6, CDKL2 POLB 1198/4885MAPT 1252/4885ALDH1A1 3585/4885
US-11970491-B2 N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds CDK4, CDK6, CDK3 POLB 1450/4885MAPT 1426/4885ALDH1A1 3706/4885
US-20220267315-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS CDK4, CDK6, CDK3 POLB 1450/4885MAPT 1426/4885ALDH1A1 3706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.